
Zealand Pharma and Deka Research & Development have partnered up to developed an infusion pump system, which will include the drug dasiglucagon, meant to treat patients with congenital hyperinsulinism (CHI), which is severe and persistent low blood sugar, Zealand Pharma reports in a press release.
Hyperinsulinism is a genetic disorder that causes improper levels of blood sugar due to abnormally high insulin amounts in the body.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app